Cyclophosphamide: Time to Say Goodnight and Goodbye?

Author(s): Catherine Edwards, David Isenberg

Journal Name: Current Rheumatology Reviews

Volume 1 , Issue 2 , 2005

Become EABM
Become Reviewer
Call for Editor


For over 20 years cyclophosphamide, either intravenous or oral, has been widely used in the treatment of patients with lupus nephritis, cerebritis and vasculitis. Although clearly beneficial for many patients, its propensity to cause haematological complications and reduced fertility has made it unpopular with both patients and physicians. The introduction of mycophenalate mofetil, and the exciting potential for other forms of therapy including B cell depletion, the B cell toleragen LJP394 and anti-BlyS antibodies, now makes it possible to consider the future of the treatment of patients with lupus without resorting to cyclophosphamide. This review considers how close we are to achieving this goal.

Keywords: immunosuppressants, leukaemia, cns lupus, mycophenalate mofetil (mmf), cytotoxicity, arthritis, methotrexate, anti-dsdna antibodies, b lymphocyte stimulator

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Published on: 01 March, 2012
Page: [189 - 191]
Pages: 3
DOI: 10.2174/1573397054023155
Price: $65

Article Metrics

PDF: 3